Abstract

Abstract FoxP3+ regulatory T cells (Treg) are essential to prevent autoimmunity but have also been implicated in suppressing antitumor immune responses. We assessed the impact of depletion of Treg cells in 8 different syngeneic tumor models, including cancer immunotherapy-sensitive and -resistant models. Robust, rapid tumor control or regression was observed in all models tested. Analysis of both peripheral and tumor-infiltrating T cells revealed that Treg cell depletion resulted in robust proliferation and cytokine production by CD8+ T cells in lymph nodes, spleen and tumor tissue. Tumor regression was CD8+ T cell-dependent, as antibody-mediated depletion of these cells abrogated tumor regression in a representative model. Interestingly, studies using FTY720 to pharmacologically block T-cell egress from the lymph nodes suggest that following Treg depletion cancer immunotherapy-sensitive models may not require new T-cell infiltration into tumor for tumor regression. This is in contrast to an immunotherapy-resistant model, which failed to regress following Treg depletion when lymph node egress was concurrently blocked. These data suggest that Treg cells play a critical role in suppressing both priming of novel anti-tumor CD8+ T-cell responses as well as limiting effector functionality of tumor-infiltrating CD8+ T cells within the tumor microenvironment. Citation Format: Yingyun Wang, Teresita Delfino, Jill M. Schartner, Sascha Rutz. Targeted ablation of FoxP3+ T cells activates peripheral and tumor-infiltrating cytotoxic CD8+ T cells in multiple syngeneic mouse tumor models [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology and Immunotherapy; 2018 Nov 27-30; Miami Beach, FL. Philadelphia (PA): AACR; Cancer Immunol Res 2020;8(4 Suppl):Abstract nr B94.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call